# Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Autism Spectrum Disorder and Associated GI Symptoms (SPROUT)

> **NCT03829878** · PHASE2 · WITHDRAWN · sponsor: **Finch Research and Development LLC.**

## Conditions studied

- Autism Spectrum Disorder
- Autism
- ASD
- Autistic Thinking
- Autistic Behavior
- Finch
- FMT
- Fecal Microbiota Transplant
- CP101
- SPROUT
- Fecal Transplant

## Interventions

- **DRUG:** CP101
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03829878
- **Lead sponsor:** Finch Research and Development LLC.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-05
- **Primary completion:** 2020-05
- **Final completion:** 2021-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study not started
- **Last updated:** 2021-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03829878

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03829878, "Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Autism Spectrum Disorder and Associated GI Symptoms (SPROUT)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03829878. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*